Navigation Links
Moleac Announces Breakthrough Results on Neuroprotective and Neurogenerative Properties of NeuroAiD

SINGAPORE, Feb. 11 /PRNewswire-Asia/ -- The January issue of "Neuropharmacology", publishes the article entitled "Neuroprotective and Neuroproliferative Activities of NeuroAiD", reporting pharmacological data establishing NeuroAiD (MLC 601) protective effects on neuronal and brain injuries as well as its effectiveness in neurological functions recovery.

The French research team was led by Prof. Michel Lazdunski, world-renowned specialist of pharmacology.

The data demonstrates NeuroAiD effects on decreasing cognitive deficits, preventing death of threatened neuronal tissues and improving functional outcomes by repairing and restoring neuronal circuits. This is fully consistent with clinical observations of NeuroAiD efficacy as a post stroke treatment.

NeuroAiD treatment increases survival rate, reduces infarct volume, prevents neuronal death and drastically decreases functional deficits in rodents' stroke models. The data also shows NeuroAiD effectiveness in reducing stroke severity when administrated preventively.

The results show that NeuroAiD triggers the synthesis of Brain Derived Neurotrophic Factor (BDNF), which is known to promote neuroplasticity. Indeed NeuroAiD induces neurogenesis in rodent and human cells, and stimulates the development of new neuronal circuits of information.

Previous trials and clinical reports conducted in Asia have already demonstrated high levels of NeuroAiD safety and efficacy in improving stroke rehabilitation, even when taken several months after stroke onset. NeuroAiD Stroke Treatment is already available in many countries in Asia and in the Middle East for stroke survivors. New clinical assessments will be conducted in France and Europe shortly on stroke recovery.

David Picard, CEO of Moleac, said "We are extremely enthusiastic and proud to see these data published. It is a strong validation of our research of active ingredients in NeuroAiD as well as of our efforts towards continuous optimization of its formula. These results pave the way for new indications of NeuroAiD beyond stroke recovery such as prevention, cognitive impairments and dementia. It is good news for patients who are in need of treatment in this under-served therapeutic area."

About Moleac

Moleac is a Singapore-based biopharmaceutical company that dedicates itself in finding and developing new medicines for the unmet needs of patients worldwide.

About NeuroAiD

NeuroAiD is a stroke treatment to help stroke patients achieve faster and better recovery. NeuroAiD is derived from natural components, carefully selected for their efficacy and absence of side effects. It currently reaches out to patients in over 25 countries.

    Contact details:

     Kasia Kaminska
     Tel: +65-64789432




Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Moleac Named Singapore Entrepreneurial Company of the Year at the Frost & Sullivan Excellence in Healthcare Awards
2. Moleac Launches NeuroAid10(TM) in the United States
3. Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing
4. Kinexus Announces the Launch of a New Protein Kinase Microarray
5. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
6. Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results
7. Silicon Kinetics Announces New Biosensor Chips With Wide Palette of Surface Chemistries
8. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
9. Healthcare Data Solutions Announces Expansion of its Healthcare Customer Solutions Team With Two Key Additions
10. Angiotech Pharmaceuticals Announces Conference Call and Webcast
11. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... In harsh ... Insertion points for in-line sensors can represent a weak spot where leaking process ... series of retractable sensor housings , which are designed to tolerate extreme process ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... OrthoAccel® Technologies, Inc., on being named to Deloitte's 2015 Technology Fast 500 list ... facility, OrthoAccel manufactures AcceleDent®, a FDA-cleared, Class II medical device that speeds up ...
(Date:11/24/2015)... ANGELES , Nov. 24, 2015 ... biotechnology company focused on the discovery, development and commercialization ... , Ph.D., Chief Executive Officer, is scheduled to present ... 1, 2015 at 10:50 a.m. EST, at The Lotte ... City . . ...
(Date:11/24/2015)... 24, 2015  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ... company,s president and chief executive officer, will present at the ... in New York City . The presentation ... 1, 2015 at 9:30 a.m. EST. ... website at least 15 minutes prior to the presentation to ...
Breaking Biology Technology:
(Date:11/17/2015)... PARIS , November 17, 2015 ... November 2015.   --> Paris from ... --> DERMALOG, the biometrics innovation leader, has invented the ... and fingerprints on the same scanning surface. Until now two ... fingerprints. Now one scanner can capture both on the same ...
(Date:11/17/2015)... Nov. 17, 2015  Vigilant Solutions announces today that ... Board of Directors. --> ... retiring from the partnership at TPG Capital, one of ... over $140 Billion in revenue.  He founded and led ... the TPG companies, from 1997 to 2013.  In his ...
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced expansion of its TDDI ... touch controller and display driver integration (TDDI) ... smartphones. These new TDDI products add to the ... resolution), TD4302 (WQHD resolution), and TD4322 (FHD resolution) ...
Breaking Biology News(10 mins):